Yahoo Finance EN

Barclays Raises Hims & Hers (HIMS) Target to $29 After Novo Deal Clears Legal Overhang — Canaccord Cuts Progyny (PGNY) on Cautious 2026 Outlook

Mar 11, 2026 &03101111202631; 14:10 UTC finance.yahoo.com Trending 3/5

Read original on finance.yahoo.com ↗

→

Neutral impact

Sentiment score: -5/100

Moderate impact Short-term (days)

WHAT THIS MEANS

Barclays upgraded Hims & Hers (HIMS) price target to $29 following clearance of legal concerns related to a Novo Nordisk deal, while Canaccord downgraded Progyny (PGNY) citing cautious 2026 outlook. These divergent analyst moves reflect selective optimism in the telehealth/fertility sectors with mixed near-term sentiment.

AI CONFIDENCE

72% High

SENTIMENT GAUGE

NEWS POWER SCORE

AFFECTED ASSETS

↑

HIMS

HIMSStock

Expected to rise

Barclays price target raise to $29 removes legal overhang from Novo deal, improving growth visibility and reducing execution risk

↓

PGNY

PGNYStock

Expected to decline

Canaccord downgrade driven by cautious 2026 guidance, suggesting slower growth trajectory and potential margin pressures ahead

PRICE HISTORY

Loading chart...

⚡ SUGGESTED ACTION

Consider long HIMS on Barclays upgrade with legal clarity as catalyst, while avoiding PGNY until 2026 guidance improves. Monitor telehealth sector momentum as HIMS strength may indicate broader sector recovery.

KEY SIGNALS

Legal risk removal for HIMS supports upside momentumAnalyst price target increase indicates improved convictionPGNY weakness reflects sector-wide caution on 2026 demandDivergent sector sentiment suggests selective opportunity

SECTORS INVOLVED

HealthcareTelehealthFertility ServicesPharmaceuticals

Analysis generated on Mar 12, 2026 at 01:07 UTC

Disclaimer: This analysis is generated by artificial intelligence for informational purposes only and does not constitute financial advice, investment recommendation, or solicitation. Original reporting by Yahoo Finance. Always conduct your own research and consult a qualified financial advisor before making investment decisions.

Barclays Raises Hims & Hers (HIMS) Target to $29 After Novo Deal Clears Legal Overhang — Canaccord Cuts Progyny (PGNY) on Cautious 2026 Outlook

RELATED INTELLIGENCE